Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters

In Austria, newborns have been screened for cystic fibrosis (CF) by analyzing immunoreactive trypsinogen (IRT) from dried blood spots (DBS)s for nearly 20 years. Recently, pancreatitis-associated protein (PAP) analysis was introduced as a second-tier test with the aim of reducing recalls for second...

Full description

Bibliographic Details
Main Authors: Maximilian Zeyda, Andrea Schanzer, Pavel Basek, Vera Bauer, Ernst Eber, Helmut Ellemunter, Margit Kallinger, Josef Riedler, Christina Thir, Franz Wadlegger, Angela Zacharasiewicz, Sabine Renner
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/11/2/299
id doaj-0c732fa4448743ad86b9611d8061a258
record_format Article
spelling doaj-0c732fa4448743ad86b9611d8061a2582021-02-14T00:01:16ZengMDPI AGDiagnostics2075-44182021-02-011129929910.3390/diagnostics11020299Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier ParametersMaximilian Zeyda0Andrea Schanzer1Pavel Basek2Vera Bauer3Ernst Eber4Helmut Ellemunter5Margit Kallinger6Josef Riedler7Christina Thir8Franz Wadlegger9Angela Zacharasiewicz10Sabine Renner11Clinical Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, 1090 Vienna, AustriaClinical Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, 1090 Vienna, AustriaUniversity Clinic for Paediatric and Adolescent Medicine, University Hospital Salzburg, 5020 Salzburg, AustriaDepartment of Pediatrics and Adolescent Medicine, Klinikum Wels-Grieskirchen, 4600 Wels, AustriaDivision of Pediatric Pulmonology and Allergology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, 8036 Graz, AustriaDepartment of Child and Adolescent Health, Division of Cardiology, Pulmonology, Allergology, and Cystic Fibrosis, Cystic Fibrosis Centre, Medical University of Innsbruck, 6020 Innsbruck, AustriaPEK Hospital Steyr Departement of Pediatrics and Adolescent Medicine, 4400 Steyr, AustriaDepartment of Pediatrics and Adolescent Medicine, Kardinal Schwarzenberg Hospital Schwarzach, 5620 Schwarzach, AustriaDepartment of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, 4040 Linz, AustriaDivision of Pediatric Pulmonology and Allergology, Department of Pediatrics and Adolescent Medicine, Hopital Klagenfurt am Wörthersee, 9020 Klagenfurt am Wörthersee, AustriaDepartment of Pediatrics and Adolescent Medicine, Klinikum Ottakring, Wilhelminenspital, Teaching Hospital of the University of Vienna, 1010 Vienna, AustriaClinical Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, 1090 Vienna, AustriaIn Austria, newborns have been screened for cystic fibrosis (CF) by analyzing immunoreactive trypsinogen (IRT) from dried blood spots (DBS)s for nearly 20 years. Recently, pancreatitis-associated protein (PAP) analysis was introduced as a second-tier test with the aim of reducing recalls for second DBS cards while keeping sensitivity high. For 28 months, when IRT was elevated (65-130 ng/ml), PAP was measured from the first DBS (<i>n </i>= 198,927) with a two-step cut-off applied. For the last 12 months of the observation period (<i>n </i>= 85,421), an additional IRT×PAP cut-off was introduced. If PAP or IRT×PAP were above cut-off, a second card was analyzed for IRT and in case of elevated values identified as screen-positive. Above 130 ng/mL IRT in the first DBS, newborns were classified as screen-positive. IRT analysis of first DBS resulted in 1,961 (1%) tests for PAP. In the first 16 months, 26 of 93 screen-positive were confirmed to have CF. Two false-negatives have been reported (sensitivity = 92.8%). Importantly, less than 30% of families compared to the previous IRT-IRT screening scheme had to be contacted causing distress. Adding IRT×PAP caused a marginally increased number of second cards and sweat tests to be requested during this period (15 and 3, respectively) compared to the initial IRT-PAP scheme. One case of confirmed CF was found due to IRT×PAP, demonstrating an increase in sensitivity. Thus, the relatively simple and economical algorithm presented here performs effectively and may be a useful model for inclusion of CF into NBS panels or modification of existing schemes.https://www.mdpi.com/2075-4418/11/2/299neonatal screeningrecallsfalse-positivesIRT×PAPIRT-PAP
collection DOAJ
language English
format Article
sources DOAJ
author Maximilian Zeyda
Andrea Schanzer
Pavel Basek
Vera Bauer
Ernst Eber
Helmut Ellemunter
Margit Kallinger
Josef Riedler
Christina Thir
Franz Wadlegger
Angela Zacharasiewicz
Sabine Renner
spellingShingle Maximilian Zeyda
Andrea Schanzer
Pavel Basek
Vera Bauer
Ernst Eber
Helmut Ellemunter
Margit Kallinger
Josef Riedler
Christina Thir
Franz Wadlegger
Angela Zacharasiewicz
Sabine Renner
Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters
Diagnostics
neonatal screening
recalls
false-positives
IRT×PAP
IRT-PAP
author_facet Maximilian Zeyda
Andrea Schanzer
Pavel Basek
Vera Bauer
Ernst Eber
Helmut Ellemunter
Margit Kallinger
Josef Riedler
Christina Thir
Franz Wadlegger
Angela Zacharasiewicz
Sabine Renner
author_sort Maximilian Zeyda
title Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters
title_short Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters
title_full Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters
title_fullStr Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters
title_full_unstemmed Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters
title_sort cystic fibrosis newborn screening in austria using pap and the numeric product of pap and irt concentrations as second-tier parameters
publisher MDPI AG
series Diagnostics
issn 2075-4418
publishDate 2021-02-01
description In Austria, newborns have been screened for cystic fibrosis (CF) by analyzing immunoreactive trypsinogen (IRT) from dried blood spots (DBS)s for nearly 20 years. Recently, pancreatitis-associated protein (PAP) analysis was introduced as a second-tier test with the aim of reducing recalls for second DBS cards while keeping sensitivity high. For 28 months, when IRT was elevated (65-130 ng/ml), PAP was measured from the first DBS (<i>n </i>= 198,927) with a two-step cut-off applied. For the last 12 months of the observation period (<i>n </i>= 85,421), an additional IRT×PAP cut-off was introduced. If PAP or IRT×PAP were above cut-off, a second card was analyzed for IRT and in case of elevated values identified as screen-positive. Above 130 ng/mL IRT in the first DBS, newborns were classified as screen-positive. IRT analysis of first DBS resulted in 1,961 (1%) tests for PAP. In the first 16 months, 26 of 93 screen-positive were confirmed to have CF. Two false-negatives have been reported (sensitivity = 92.8%). Importantly, less than 30% of families compared to the previous IRT-IRT screening scheme had to be contacted causing distress. Adding IRT×PAP caused a marginally increased number of second cards and sweat tests to be requested during this period (15 and 3, respectively) compared to the initial IRT-PAP scheme. One case of confirmed CF was found due to IRT×PAP, demonstrating an increase in sensitivity. Thus, the relatively simple and economical algorithm presented here performs effectively and may be a useful model for inclusion of CF into NBS panels or modification of existing schemes.
topic neonatal screening
recalls
false-positives
IRT×PAP
IRT-PAP
url https://www.mdpi.com/2075-4418/11/2/299
work_keys_str_mv AT maximilianzeyda cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
AT andreaschanzer cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
AT pavelbasek cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
AT verabauer cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
AT ernsteber cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
AT helmutellemunter cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
AT margitkallinger cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
AT josefriedler cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
AT christinathir cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
AT franzwadlegger cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
AT angelazacharasiewicz cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
AT sabinerenner cysticfibrosisnewbornscreeninginaustriausingpapandthenumericproductofpapandirtconcentrationsassecondtierparameters
_version_ 1724271302168018944